Provided By GlobeNewswire
Last update: Mar 31, 2025
Rapid Enrollment and Dosing of First Patients in PRECISE-AD Trial Underscores the Unmet Need for Better Treatment Options for Alzheimer’s Disease
PROMIS NEUROSCIENCES INC
NASDAQ:PMN (8/22/2025, 8:00:00 PM)
0.5359
-0.01 (-2.39%)
Find more stocks in the Stock Screener